The Winner of ASCO 2010: Bristol Myers Squibb

Sun, 07/04/2010 - 09:35 EDT - Seeking Alpha

Ohad Hammer submits:The hottest theme at this year’s 2010 ASCO (American Society of Clinical Oncology) annual meeting was without a doubt cancer immunotherapy, an old paradigm that deals with redirecting the patient’s immune system against tumors. After decades of failures, this concept is finally proving itself useful. There are basically two approaches: 1) cancer vaccines that aim at eliciting an immune response against specific targets on cancer cells and 2) immunomodulatory drugs that aim at stimulating the immune system in a more general manner (not target specific). The undisputed leader in cancer vaccines is Dendreon (DNDN), which currently has the only FDA approved cancer vaccine. Following ASCO, it looks like the leader in immunomodulation drugs is Bristol Myers Squibb (BMY) (also referred to as "BMS" in this article).Complete Story »

Original article
Login or register to post comments

Immunotherapy Comes Of Age At ASCO 2012
By The Swiss Trader:Until just recently, immunotherapy (or stimulation of the immune system to treat disease) was regarded as an ill-conceived approach in cancer drug development. Many scientists and investors did not consider immunotherapy treatment to be a legitimate area of cancer research. The skepticism was not totally unfounded as there had been years of failures, such as those from CancerVax, IDM, and Cell Genesys to name a few.
Peregrine Pharmaceuticals, The Little Biotech With The Golden Goose Of Immunotherapy
By Chris Lacoursiere:The annual conference of The American Society of Clinical Oncology (ASCO) is currently less than a few days away, and what is the buzz for this year's conference? Immunotherapy is the buzz word for this year's conference.
Ipilimumab Approval Highlights Active Immunotherapy Renaissance
Michael Becker submits:On Friday, March 25, 2011, the U.S. Food and Drug Administration [FDA] approved Yervoy® [ipilimumab] by Bristol-Myers Squibb (BMY) for the treatment of patients with late-stage [metastatic] melanoma. With the news, ipilimumab becomes the eleventh monoclonal antibody [mAb] approved for the treatment of cancer.
Important ASCO Updates On Immunotherapy Drug Treatments
By Andrew J. Norris: Some of the more exciting developments at this year's annual meeting of the American Society of Clinical Oncology (ASCO) which is on its last day (June 1-5) are clearly Immunotherapy treatments.
Investing in Cancer Therapy? Consider Companies Engaged in Immunotherapy
Edward Stevenson submits:As the first FDA-approved immunotherapy, Dendreon's (DNDN) Provenge significantly reduced the barriers to entry for firms seeking regulatory approval of immune-based therapies. The first mover advantage also scored Dendreon a lofty $6.12B valuation.
Similarities Between the First Two Active Immunotherapies in Cancer
Michael Becker submits:Approval of Bristol-Myers Squibb’s (BMY) Yervoy [ipilimumab] for melanoma in March 2011 marked the second victory for the field of active immunotherapy in oncology within a year, with the first being the U.S.
Drugs To Watch At ASCO 2012
By Ohad Hammer:Below is a list of drugs and companies which will have meaningful data at this year's annual meeting of American Society of Clinical Oncology (ASCO). As I will be attending this year's conference, I will try to write updates on a regular basis. Feel free to send me questions or post them as comments to this post. PD1 antibodies - the next big thing in oncology
Bristol Myers Squibb And The New Wave Of Cancer Drugs
By Peter Geschek:Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance.A new wave of immunotherapy drugs, in the spotlight of the upcoming ASCO (American Society of Clinical Oncology) meeting, promises to produce longer-lasting remissions.
Adjuvants May Hold Key To Unlocking Cancer Immunotherapy Revolution
By Michael Becker:The FDA approval of sipuleucel-T (Provenge), a patient-specific immunotherapy for androgen independent prostate cancer developed by Dendreon Corporation (DNDN), and ipilimumab (Yervoy), the first immune check point molecule for melanoma by Bristol-Myers Squibb (BMY), has renewed interest in the concept of immunotherapy as an approach
Overcoming The Challenges Of Cell-Based Cancer Immunotherapy
By Andrew J. Norris: Unlike chemotherapy, which directly attacks cancer cells, immunotherapy stimulates a patient's immune system to attack tumors and ultimately prolong survival. Autologous cellular immunotherapy, such as Dendreon's (DNDN) sipuleucel-T (Provenge), uses patients' own immune cells to defend against cancer as these cells are best known as nature's adjuvants and are very powerful in eliciting an immune response.

Main menu

Secondary menu

The Winner of ASCO 2010: Bristol Myers Squibb

Related

Latest

User login

Our Blog

Markets Map

Follow Us

Secondary menu